{"id":"efdab765-ea42-5e82-be53-b3b500f82c88","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:taxane-followup","predicate":"increases_in_recorded_comparison","statement":"The taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"cf36b446-7b0c-53f2-bda3-47a2f5ef6ffb","mechanism_event_label":"The taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"cf36b446-7b0c-53f2-bda3-47a2f5ef6ffb","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:taxane-followup-event","event_type":"experimental_observation","label":"The taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.","description":"### taxane-followup\n\nThe taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.\nAverage difference −1.39 points (95% CI −2.48 to −0.30), P=0.01. Significant separation at weeks 24,36,52; the 104-week point alone was not significant (P=0.17).\nModel and exposure: Same S0715 cohort, not an independent replication; longitudinal FACT-NTX model, 12–104 weeks.\nLimitations: Outcome sign denotes worse neuropathy, not the decreasing FACT-NTX score. Same cohort as the 2013 trial; no automatic transfer to every neuropathy cause.\nReference: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). | 2018 | https://pubmed.ncbi.nlm.nih.gov/29361042/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6005110/ | https://doi.org/10.1093/jnci/djx259 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Original 3-g/day ALCAR allocation","sequence_order":0,"notes":""},{"entity":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"0727cb60-dd74-52d0-ac12-86697e75ac71","slug":"paclitaxel","display_name":"Paclitaxel","entity_type_key":"small_molecule"},"role":"one permitted taxane regimen","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"93c810d6-7f5f-5591-8bb2-ad1897aa03f8","slug":"docetaxel","display_name":"Docetaxel","entity_type_key":"drug"},"role":"alternative taxane regimen","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Original 3-g/day ALCAR allocation\", \"comparator\": \"Original placebo allocation\", \"endpoint\": \"The taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Same S0715 cohort, not an independent replication; longitudinal FACT-NTX model, 12–104 weeks.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Outcome sign denotes worse neuropathy, not the decreasing FACT-NTX score. Same cohort as the 2013 trial; no automatic transfer to every neuropathy cause.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). | https://pubmed.ncbi.nlm.nih.gov/29361042/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6005110/ | https://doi.org/10.1093/jnci/djx259","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference taxane-followup; Average difference −1.39 points (95% CI −2.48 to −0.30), P=0.01. Significant separation at weeks 24,36,52; the 104-week point alone was not significant (P=0.17).","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3c288418-c6bf-5ac7-ad08-1cbfbe7c81fa","evidence_kind":"source_excerpt","locator":"Lines 559-565","start_line":559,"end_line":565,"excerpt":"### taxane-followup\n\nThe taxane trial follow-up found worse average neuropathy over two years after 24 weeks of ALCAR.\nAverage difference −1.39 points (95% CI −2.48 to −0.30), P=0.01. Significant separation at weeks 24,36,52; the 104-week point alone was not significant (P=0.17).\nModel and exposure: Same S0715 cohort, not an independent replication; longitudinal FACT-NTX model, 12–104 weeks.\nLimitations: Outcome sign denotes worse neuropathy, not the decreasing FACT-NTX score. Same cohort as the 2013 trial; no automatic transfer to every neuropathy cause.\nReference: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). | 2018 | https://pubmed.ncbi.nlm.nih.gov/29361042/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6005110/ | https://doi.org/10.1093/jnci/djx259 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Same S0715 cohort, not an independent replication; longitudinal FACT-NTX model, 12–104 weeks.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}